Presence of nitrosamine impurities in medicinal products

1World Health Organization (WHO). Information Note Nitrosamine impurities [displayed 24 September 2020]. Available at https://www.who.int/medicines/publications/drugalerts/InformationNote_Nitrosamine-impurities/en/World Health Organization (WHO) Information Note Nitrosamine impurities [displayed 24 September 2020] Available at https://www.who.int/medicines/publications/drugalerts/InformationNote_Nitrosamine-impurities/en/Search in Google Scholar

2International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk [displayed 7 March 2021]. p. 6. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdfInternational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk [displayed 7 March 2021] p. 6. Available at https://www.ema.europa.eu/en/documents/scientific-guideline/ch-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdfSearch in Google Scholar

3European Medicines Agency (EMA). Procedure under Article 5(3) of Regulation EC (No) 726/2004. Nitrosamine impurities in human medicinal products [displayed 24 September 2020]. Available at https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdfEuropean Medicines Agency (EMA) Procedure under Article 5(3) of Regulation EC (No) 726/2004. Nitrosamine impurities in human medicinal products [displayed 24 September 2020] Available at https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdfSearch in Google Scholar

4European Medicines Agency (EMA). Lessons learnt from presence of N-nitrosamine impurities in sartan medicines [displayed 24 September 2020]. Available at https://www.ema.europa.eu/en/documents/report/lessons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdfEuropean Medicines Agency (EMA) Lessons learnt from presence of N-nitrosamine impurities in sartan medicines [displayed 24 September 2020] Available at https://www.ema.europa.eu/en/documents/report/essons-learnt-presence-n-nitrosamine-impurities-sartan-medicines_en.pdfSearch in Google Scholar

5Šulc M, Hodek P, Stiborová M. The binding affinity of c a r c in o gen i c N- nit r o so dim et h y l a mine a n d N-nitrosomethylaniline to cytochromes P450 2B4, 2E1 and 3A6 does not dictate the rate of their enzymatic N-demethylation. Gen Physiol Biophys 2010;29:175-85. doi: 10.4149/gpb_2010_02_175Šulc M Hodek P Stiborová M The binding affinity of c a r c in o gen i c N- nit r o so dim et h y l a mine a n d N-nitrosomethylaniline to cytochromes P450 2B4, 2E1 and 3A6 does not dictate the rate of their enzymatic N-demethylation Gen Physiol Biophys 201029175 85 10.4149/gpb_2010_02_17520577029Open DOISearch in Google Scholar

6European Medicines Agency (EMA). Assessment report Referral under Article 31 of Directive 2001/83/EC [displayed 24 September 2020]. Available at https://www.ema.europa.eu/en/documents/variation-report/sartans-article-31-referral-chmp-assessment-report_en.pdfEuropean Medicines Agency (EMA) Assessment report Referral under Article 31 of Directive 2001/83/EC [displayed 24 September 2020] Available at https://www.ema.europa.eu/en/documents/variation-report/sartans-article-31-referral-chmp-assessment-report_en.pdfSearch in Google Scholar

7Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [displayed 7 March 2021]. Available at https://eur-lex.europa.eu/eli/dir/2001/83/Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [displayed 7 March 2021] Available at https://eur-lex.europa.eu/eli/dir/2001/83/Search in Google Scholar

8European Medicines Agency (EMA). EU inspection finds Zhejiang Huahai site non-compliant for manufacture of valsartan: EMA and national authorities considering impact on other active substances produced at the site [displayed 24 September 2020]. Available at https://www.ema.europa.eu/en/news/eu-inspection-finds-zhejiang-huahai-site-non-compliant-manufacture-valsartan-ema-nationalEuropean Medicines Agency (EMA) EU inspection finds Zhejiang Huahai site non-compliant for manufacture of valsartan: EMA and national authorities considering impact on other active substances produced at the site [displayed 24 September 2020] Available at https://www.ema.europa.eu/en/news/eu-inspection-finds-zhejiang-huahai-site-non-compliant-manufacture-valsartan-ema-nationalSearch in Google Scholar

9European Medicines Agency (EMA). Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities [displayed 24 September 2020]. Available at https://www.ema.europa.eu/en/news/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impuritiesEuropean Medicines Agency (EMA) Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities [displayed 24 September 2020] Available at https://www.ema.europa.eu/en/news/sartan-medicines-companies-review-manufacturing-processes-avoid-presence-nitrosamine-impuritiesSearch in Google Scholar

10European Medicines Agency (EMA). Nitrosamine impurities [displayed 24 September 2020]. Available at https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities#metformin-containing-medicines-sectionEuropean Medicines Agency (EMA) Nitrosamine impurities [displayed 24 September 2020] Available at https://www.ema.europa.eu/en/human-regulatory/post-authorisation/referral-procedures/nitrosamine-impurities#metformin-containing-medicines-sectionSearch in Google Scholar

11World Health Organization (WHO). Guidelines for Drinking-water Quality. 3^rd ed. Vol 1, Incorporating first and second addenda. Geneva; WHO; 2008.World Health Organization (WHO) Guidelines for Drinking-water Quality. 3^rd ed. Vol 1, Incorporating first and second addenda Geneva WHO 2008Search in Google Scholar

12Krul CAM, Zeilmaker MJ, Schothorst RC, Havenaar R. Intragastric formation and modulation of N-nitrosodimethylamine in a dynamic in vitro gastrointestinal model under human physiological conditions. Food Chem Toxicol 2004;42:51-63. doi: 10.1016/j.fct.2003.08.005Krul CAM Zeilmaker MJ Schothorst RC Havenaar R Intragastric formation and modulation of N-nitrosodimethylamine in a dynamic in vitro gastrointestinal model under human physiological conditions Food Chem Toxicol 20044251 63 10.1016/j.fct.2003.08.00514630130Open DOISearch in Google Scholar

13Song P, Wu L, Guan W. Dietary nitrates, nitrites, and nitrosamines intake and the risk of gastric cancer: A meta-analysis. Nutrients 2015;7:9872-95. doi: 10.3390/nu7125505Song P Wu L Guan W Dietary nitrates, nitrites, and nitrosamines intake and the risk of gastric cancer: A meta-analysis Nutrients 201579872 95 10.3390/nu7125505469005726633477Open DOISearch in Google Scholar

14Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Medicinal products database [displayed 24 September 2020]. Available at https://www.halmed.hr/Lijekovi/Baza-lijekova/Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Medicinal products database [displayed 24 September 2020] Available at https://www.halmed.hr/Lijekovi/Baza-lijekova/Search in Google Scholar

15Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Obavijest o nestašici lijekova s djelatnom tvari ranitidin [Notice of shortage of drugs with the active substance ranitidine, in Croatian] [displayed 24 September 2020]. Available at https://www.halmed.hr/Novosti-i-edukacije/Novosti/2019/Obavijest-o-nestasici-lijekova-s-djelatnom-tvari-ranitidin-/2239Agency for Medicinal Products and Medical Devices of Croatia (HALMED) Obavijest o nestašici lijekova s djelatnom tvari ranitidin [Notice of shortage of drugs with the active substance ranitidine, in Croatian] [displayed 24 September 2020] Available at https://www.halmed.hr/Novosti-i-edukacije/Novosti/2019/Obavijest-o-nestasici-lijekova-s-djelatnom-tvari-ranitidin-/2239Search in Google Scholar

16Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Obustava izvršenja odobrenja za stavljanje u promet lijekova koji sadrže djelatnu tvar ranitidin u Europskoj uniji [Suspension of the marketing authorization for medicinal products containing the active substance ranitidine in the European Union, in Croatian] [displayed 24 September 2020]. Available at https://www.halmed.hr/Novosti-i-edukacije/Novosti/2020/Obustava-izvrsenja-odobrenja-za-stavljanje-u-promet-lijekova-koji-sadrze-djelatnu-tvar-ranitidin-u-Europskoj-uniji/2360/Agency for Medicinal Products and Medical Devices of Croatia (HALMED) Obustava izvršenja odobrenja za stavljanje u promet lijekova koji sadrže djelatnu tvar ranitidin u Europskoj uniji [Suspension of the marketing authorization for medicinal products containing the active substance ranitidine in the European Union, in Croatian] [displayed 24 September 2020] Available at https://www.halmed.hr/Novosti-i-edukacije/Novosti/2020/Obustava-izvrsenja-odobrenja-za-stavljanje-u-promet-lijekova-koji-sadrze-djelatnu-tvar-ranitidin-u-Europskoj-uniji/2360/Search in Google Scholar

17Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Izvješće o potrošnji lijekova u Republici Hrvatskoj u 2018. [Report on medicinal product utilization in the Republic of Croatia in 2018, in Croatian] [displayed 24 September 2020]. Available at https://halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2018/Agency for Medicinal Products and Medical Devices of Croatia (HALMED) Izvješće o potrošnji lijekova u Republici Hrvatskoj u 2018. [Report on medicinal product utilization in the Republic of Croatia in 2018, in Croatian] [displayed 24 September 2020] Available at https://halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2018/Search in Google Scholar

18Agency for Medicinal Products and Medical Devices of Croatia (HALMED). Izvješće o potrošnji lijekova u Republici Hrvatskoj u 2019. [Report on medicinal product utilization in the Republic of Croatia in 2019, in Croatian] [displayed 24 September 2020]. Available at https://halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2019/Agency for Medicinal Products and Medical Devices of Croatia (HALMED) Izvješće o potrošnji lijekova u Republici Hrvatskoj u 2019. [Report on medicinal product utilization in the Republic of Croatia in 2019, in Croatian] [displayed 24 September 2020] Available at https://halmed.hr/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-potrosnji-lijekova/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2019/Search in Google Scholar